Curasight A/S has successfully completed a directed issue of shares of approximately DKK 16.4 million and has entered into a new loan facility

The Directed Issue

The Board of Directors of Curasight has, based on authorization from the general meeting stated in article 5.1.2 of the Company's articles of association resolved on a directed issue of 2,055,330 shares. The Subscription Price in the Directed Issue amounts to DKK 7.98 per share and has been determined through an accelerated bookbuilding procedure carried out by Sedermera. The Subscription Price corresponds to a discount of approximately 3 percent in relation to the volume weighted average price (VWAP) of the Company's share on Spotlight Stock Market during the period from and including 2025-11-17 to and including 2025-12-12.

Prior to the Directed Issue, the Company's Board of Directors has made an overall assessment and carefully considered the possibility of raising capital through a rights issue. The Board of Directors considers that the reasons for deviating from the shareholders' pre-emption right are (i) that a rights issue would take a significantly longer time to complete and entail a higher risk for a material adverse effect on the share price, (ii) to diversify and strengthen the Company's shareholder base with Nordic, international, institutional and professional investors, and to strengthen the share's liquidity, (iii) carrying out a directed share issue can be made at lower costs and with less complexity than a rights issue and, the Board of Directors has assessed that a rights issue would also entail a risk of not being fully subscribed or necessitate significant underwriting commitments from a guarantor syndicate that would entail additional costs and/or additional dilution depending on the type of remuneration for such underwriting, and (iv) to ensure a strong balance sheet. Considering the above, the Board of Directors has made the assessment the Directed Issue with deviation from the shareholders' pre-emptive right is the most favorable alternative for Curasight.

By establishing the Subscription Price in the Directed Issue through an accelerated bookbuilding procedure, it is the assessment of the Board of Directors that the subscription price has been determined on market terms.

Motives and use of proceeds

In order to support the clinical development of uTRACE® and uTREAT® and strengthen Curasight's financial position, the Company has chosen to carry out the Directed Issue and enter the Loan Facility. The net proceeds from the Financing are intended to be utilized as follows:

• The completion of the phase 1 study with uTREAT® (brain cancer).
• The completion of the phase 2 study with uTRACE® (prostate cancer).
• The initiation of the phase 3 study with uTRACE® (prostate cancer), together with Curium.
• Submission of an FDA Investigational New Drug (IND) application for uTREAT® in brain cancer.

The Board of Directors assesses that the net proceeds from the Financing will be sufficient to fund the Company's operations to the end of 2026.

Loan Facility

In connection with the Directed Issue, Curasight has entered into a loan agreement with Fenja Capital regarding a loan facility, divided into two tranches. The first tranche amounts to DKK 25 million and will be structured as a convertible loan (the "Convertible Loan"), of which DKK 10 million represents a refinancing of the existing loan and DKK 15 million will be paid out upon approval by the extraordinary general meeting. The Loan Facility and the issuance of the Convertible Loan are conditional upon the general meeting of the Company resolving to authorize the Board of Directors to issue the relevant convertible loan instrument to the Lender. Curasight will separately issue a notice to convene an extraordinary general meeting with a proposal for the general meeting to authorize the Board of Directors to issue convertible loan notes. The second tranche amounts to DKK 15 million and may be drawn in Q2 2026.

The loan facility carries a setup fee of 5 percent on the total facility amount. Interest on drawn amounts accrues at 1.25 percent per started 30-day period, while interest on undrawn amounts accrues at 0.4 percent per started 30-day period. The Loan facility has a maturity date of 2026-12-29, with a total convertible size of DKK 25 million. The conversion price is set at 125 percent of the subscription price in the Directed Issue.

Number of shares, share capital and dilution
Through the Directed Issue, the Company's share capital will increase by DKK 102,766.50, from DKK 2,293,375.55 to DKK 2,396,142.05, through a new issue of 2,055,330 shares, which means that the total number of shares will increase from 45,867,511 shares to 47,922,841 shares and will result in a dilution of approximately 4.29 percent of the capital for existing shareholders who did not participate in the issue.

Advisors

Sedermera Corporate Finance AB acts as Sole Global Coordinator and bookrunner in connection with the Directed Issue. DLA Piper is the Company's legal advisor.